Evaluation and treatment of nonsustained ventricular tachycardia.
The clinical significance of nonsustained ventricular tachycardia continues to undergo reevaluation as clinicians attempt to optimize screening strategies for identifying high-risk patients and to evaluate the efficacy of therapeutic interventions. The utility of ambulatory monitoring and programmed stimulation as screening tools in the patient who has suffered an infarction remains unsettled; ongoing clinical trials may help resolve these issues. New data suggest that the survival benefit associated with angiotensin-converting enzyme inhibition is unrelated to effects on spontaneous arrhythmias, similar to results previously reported for beta-blockers. Randomized clinical trials of prophylactic amiodarone in patients with congestive heart failure and nonsustained ventricular tachycardia have produced conflicting results. A strong relationship between polymorphic nonsustained ventricular tachycardia and sudden death in patients without structural heart disease or QT prolongation has been reported. The significance of nonsustained ventricular tachycardia in dilated cardiomyopathy and hypertrophic cardiomyopathy has also been reassessed.
Wilber
D J
DJ
Section of Cardiology, University of Chicago, IL 60637, USA.
D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D006332:Cardiomegaly / Q000150:complications; D002311:Cardiomyopathy, Dilated / Q000150:complications / Q000175:diagnosis; D004562:Electrocardiography; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000401:mortality; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D017180:Tachycardia, Ventricular / Q000150:complications / Q000401:mortality / Q000628:therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D014665:Vasodilator Agents; D000638:Amiodarone